MOLECULAR DOCKING ON BIOACTIVE COMPOUNDS OF GENISTEIN QUERCETIN AND RESVERATROL TO BRCA1, ERA, AND EGFR RECEPTORS IN BREAST CANCER

Authors

  • Maharani Puspita Sari H. S. Medical Undergraduate, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
  • Rara Inggarsih Department of Medical Biology, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
  • Rachmat Hidayat Department of Medical Biology, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
  • Ziske Maritska Department of Medical Biology, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
  • Triwani Department of Medical Biology, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia

DOI:

https://doi.org/10.31004/jkt.v5i3.30240

Keywords:

Molecular Docking, Genistein, Quercetin, Resveratrol, Breast Cancer

Abstract

Kanker payudara merupakan kanker yang paling banyak dijumpai dan menjadi penyebab utama kematian akibat kanker pada wanita. Berbagai fitokimia dari bahan alam berpotensi memberikan efek terapeutik terhadap kanker payudara, beberapa diantaranya adalah genistein, quercetin, dan resveratrol. Penelitian ini bertujuan untuk mengetahui interaksi senyawa bioaktif genistein, quercetin dan resveratrol terhadap reseptor brca1, era dan egfrpada kanker payudara secara in silico dengan molecular docking. Molecular docking dilakukan melalui beberapa tahapan mulai dari preparasi struktur 3D senyawa bioaktif, preparasi protein target, validasi metode molecular docking, dan docking senyawa bioaktif pada protein target. Semakin rendah nilai energi ikatan antara senyawa uji dengan protein target maka ikatan yang terbentuk akan semakin kuat dan stabil. Hasil docking menunjukkan nilai energi pengikatan kompleks genistein 

References

Adelusi, T. I., Abdul-Hammed, M., Idris, M. O., Oyedele, Q. K., & Adedotun, I. O. (2021). Molecular dynamics, quantum mechanics and docking studies of some Keap1 inhibitors – An insight into the atomistic mechanisms of their antioxidant potential. Heliyon, 7(6), e07317. https://doi.org/10.1016/j.heliyon.2021.e07317

Akash, S., Bibi, S., Biswas, P., Mukerjee, N., Khan, D. A., Hasan, M. N., Sultana, N. A., Hosen, M. E., Jardan, Y. A. B., Nafidi, H. A., & Bourhia, M. (2023). Revolutionizing anti-cancer drug discovery against breast cancer and lung cancer by modification of natural genistein: an advanced computational and drug design approach. Frontiers in Oncology, 13(September), 1–15. https://doi.org/10.3389/fonc.2023.1228865

American Cancer Society. (2022). Breast Cancer What is breast cancer? American Cancer Society. Cancer Facts and Figures Atlanta, Ga: American Cancer Society, 1–19. http://www.cancer.org/cancer/breast-cancer/about/what-is-breast-cancer.html

Annaji, M., Poudel, I., Boddu, S. H. S., Arnold, R. D., Tiwari, A. K., & Babu, R. J. (2021). Resveratrol-loaded nanomedicines for cancer applications. Cancer Reports, 4(3), 1–21. https://doi.org/10.1002/cnr2.1353Bhowmik, D., Nandi, R., Prakash, A., & Kumar, D. (2021). Evaluation of flavonoids as 2019-nCoV cell entry inhibitor through molecular docking and pharmacological analysis. Heliyon, 7(3), e06515. https://doi.org/10.1016/j.heliyon.2021.e06515

Chandran, S. C. S. (2023). Molecular docking analysis of quercetin with known CoVid-19 targets. Bioinformation, 19(11), 1081–1085. https://doi.org/10.6026/973206300191081

Chopra, I., Biosciences, E., Panwar, U., Madhavi, M., Bhrdwaj, A., Soni, L., Sharma, K., Singh, A., Eminent, P., Vineeth, B., Mohan, P., Prajapati, L., Joshi, I., Sharma, R., Agrawal, S., Khalid, B., Alzahrani, J., Hussain, T., Nayarisseri, A., & Singh, S. K. (2022). Structural insights into conformational stability of ESR1 and structure base screening of new potent inhibitor for the treatment of Breast Cancer. 1–30. https://doi.org/10.21203/rs.3.rs-1413803/v1

Downloads

Published

2024-09-03

Issue

Vol. 5 No. 3 (2024): SEPTEMBER 2024

Section

Articles

License

Copyright (c) 2024 Maharani Puspita Sari H. S., Rara Inggarsih, Rachmat Hidayat, Ziske Maritska, Triwani

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Authors who publish with this journal agree to the following terms:

  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).